PYPD
PolyPid Ltd.
$5.05
+4.55%
$92.2M
No data for this timeframe.
Vol
Market Cap$92.2M
Cap SizeMicro Cap
SEC Reports4
Press Releases3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. L3·CIK 0001611842·Prev Close $4.83
Recent Activity
May 20, 2026
Press
PolyPid management will present at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026. This
Impact 3/10
May 20, 2026
announcement
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
<p>PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” o
May 13, 2026
SEC
PolyPid reported Q1 2026 financial results and provided a corporate update. The company initiated an NDA submission to t
6-K — Impact 7/10
May 13, 2026
SEC
PolyPid reported Q1 2026 net loss of $7.7M ($0.35/share), beating consensus EPS of -$0.43 by 18.6%. The company initiate
PRESS-RELEASE — Impact 7/10
Apr 13, 2026
Press
PolyPid announced new pharmacokinetic data from its Phase 3 SHIELD II trial showing sustained, controlled release of D-P
Impact 7/10
Apr 6, 2026
SEC
Robert Benjamin Stein, an insider at PolyPid Ltd., filed a Form 3 disclosing ownership of stock options. The filing refl
3 — Impact 3/10
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.25 (Feb 2026)
Current $5.05
Low $9.00
Median $13.00
High $14.00
4 analysts
$9.00
$14.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 11, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▲ +8.0% | $-0.49 — $-0.25 | 53% YoY | 4 |
| Next Q | $-0.32 ▼ -0.5% | $-0.38 — $-0.23 | 15% YoY | 4 |
| Current FY | $-1.43 ▲ +3.2% | $-1.82 — $-1.04 | 32% YoY | 4 |
| Next FY | $-1.25 ▼ -35.7% | $-2.15 — $-0.71 | 12% YoY | 4 |
Latest Reports
NEUTRAL
Press
3/10
PolyPid management will present at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026. This
May 20, 2026
BULLISH
6-K
7/10
PolyPid reported Q1 2026 financial results and provided a corporate update. The company initiated an NDA submission to t
May 13, 2026
BULLISH
PRESS-RELEASE
7/10
PolyPid reported Q1 2026 net loss of $7.7M ($0.35/share), beating consensus EPS of -$0.43 by 18.6%. The company initiate
May 13, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.3/10.
BULLISH
6-K
7/10
PolyPid reported Q1 2026 financial results and provided a corporate update. The company initiated an
May 13, 2026
BULLISH
PRESS-RELEASE
7/10
PolyPid reported Q1 2026 net loss of $7.7M ($0.35/share), beating consensus EPS of -$0.43 by 18.6%.
May 13, 2026
NEUTRAL
3
3/10
Robert Benjamin Stein, an insider at PolyPid Ltd., filed a Form 3 disclosing ownership of stock opti
Apr 6, 2026
BULLISH
6-K
8/10
PolyPid Ltd. has initiated a rolling New Drug Application (NDA) submission to the FDA for its lead p
Mar 31, 2026
NEUTRAL
3/10
PolyPid management will present at the Craig-Hallum 23rd Annual Institutional Investor Conference on
May 20, 2026
BULLISH
7/10
PolyPid announced new pharmacokinetic data from its Phase 3 SHIELD II trial showing sustained, contr
Apr 13, 2026
BULLISH
7/10
PolyPid announced the initiation of a rolling New Drug Application (NDA) submission to the FDA for D
Mar 31, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 90% buy across 10 analysts — 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.25 mean target (Feb 2026)
$9.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $5.05 |
| Target Low | $9.00 |
| Target Mean | $12.25 |
| Target Median | $13.00 |
| Target High | $14.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.49 | $-0.25 | 53.2% | +8.0% | 3↑ 0↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.32 | $-0.38 | $-0.23 | 14.9% | -0.5% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-1.43 | $-1.82 | $-1.04 | 31.7% | +3.2% | 3↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-1.25 | $-2.15 | $-0.71 | 12.1% | -35.7% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.365 | |
| 7d ago | $-0.397 | +0.032 |
| 30d ago | $-0.397 | +0.032 |
| 60d ago | $-0.397 | +0.032 |
| 90d ago | $-0.397 | +0.032 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 11, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
announcement
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
<p>PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical
May 13, 2026
earnings
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
<p align="center"><em>Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently </em></p>
May 13, 2026
earnings_calendar
PYPD Q1 2026 Earnings Scheduled — 2026-05-13
Apr 21, 2026
Clinical Trial
D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Phase Phase 3 — COMPLETED
Apr 13, 2026
Clinical Trial
Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery.
Phase Phase 2 — COMPLETED
Apr 13, 2026
fda
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision
Apr 1, 2026
Clinical Trial
D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Phase Phase 2 — COMPLETED
Mar 31, 2026
earnings
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
<p align="center"><em>PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 </em></p>
Mar 17, 2026
other
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
<p align="center"><em>FDA </em><em>Grants $4.</em><em>3 </em><em>Million Small Business Waiver, Enabling Focus on Commercialization Preparations</em><